title: Glucagon and clonidine testing in the diagnosis of pheochromocytoma.
abstract: We assessed the sensitivity and specificity of glucagon stimulation and clonidine suppression tests in the diagnosis of pheochromocytoma in 113 hypertensive patients, 39 with and 74 without the tumor. In the glucagon stimulation test, blood was sampled 2 minutes after intravenous injection of 0.28 mumol (1 mg) glucagon, and in the clonidine suppression test, blood was sampled 3 hours after administration of oral clonidine, 1.30 mumol (0.3 mg)/70 kg body wt. Baseline levels of catechols in antecubital venous blood were abnormal, with norepinephrine greater than 7.10 nmol/l (1,200 pg/m), epinephrine greater than 1.51 nmol/l (276 pg/ml), norepinephrine/dihydroxyphenylglycol (DHPG) ratio greater than 1.09, or dopa greater than 35.53 nmol/l (7,000 pg/ml), in 30 of 39 patients with pheochromocytoma (sensitivity 77%) and 1 of 74 patients without pheochromocytoma (specificity 99%). Results of the glucagon test were abnormal (norepinephrine greater than 11.83 nmol/l [2,000 pg/ml] or more than threefold increase from baseline) in 25 of 31 patients with pheochromocytoma (sensitivity 81%) and 0 of 72 patients without pheochromocytoma (specificity 100%). Results of the clonidine test were abnormal (after clonidine norepinephrine greater than 2.96 nmol/l [500 pg/ml] or less than 50% decrease from baseline) in 29 of 30 patients with pheochromocytoma (sensitivity 97%) and in 7 of 30 patients without pheochromocytoma (specificity 67%). Very high baseline levels of catechols therefore indicated the presence of pheochromocytoma, but there were several false-negative results when normal levels were obtained. The glucagon test alone was highly specific but not sensitive, and the clonidine test was highly sensitive but less specific.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: E
authors.initials: E
authors.lastname: Grossman
authors.forename: D S
authors.initials: DS
authors.lastname: Goldstein
authors.forename: A
authors.initials: A
authors.lastname: Hoffman
authors.forename: H R
authors.initials: HR
authors.lastname: Keiser
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D002396:Catechols / Q000097:blood / Q000652:urine; D003000:Clonidine; D004359:Drug Therapy, Combination; D005934:Glucagon; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007275:Injections, Intravenous; D009411:Nerve Endings / Q000187:drug effects / Q000378:metabolism; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
chemical_list: D002396:Catechols; D010643:Phenoxybenzamine; D005934:Glucagon; C034221:catechol; D003000:Clonidine